122 related articles for article (PubMed ID: 22137626)
1. [Ustekinumab].
Ortonne JP
Ann Dermatol Venereol; 2011 Dec; 138(12):848-50. PubMed ID: 22137626
[No Abstract] [Full Text] [Related]
2. [Infliximab].
Goujon C; Bachelez H
Ann Dermatol Venereol; 2011 Dec; 138(12):839-41. PubMed ID: 22137623
[No Abstract] [Full Text] [Related]
3. [Patient education. Information letter on treatment of psoriasis with ustekinumab (Stelara)].
Groupe de recherche sur psoriasis de Société française de dermatologie, mai 2011
Ann Dermatol Venereol; 2011 Dec; 138(12):874-5. PubMed ID: 22137636
[No Abstract] [Full Text] [Related]
4. Ustekinumab (Stelara) for psoriasis.
Med Lett Drugs Ther; 2010 Jan; 52(1330):7-8. PubMed ID: 20208473
[No Abstract] [Full Text] [Related]
5. Treatment of severe psoriasis with ustekinumab during pregnancy.
Andrulonis R; Ferris LK
J Drugs Dermatol; 2012 Oct; 11(10):1240. PubMed ID: 23134993
[TBL] [Abstract][Full Text] [Related]
6. Brodalumab versus ustekinumab in psoriasis.
Fioranelli M; Roccia MG; Lotti T
Dermatol Ther; 2016 Sep; 29(5):298. PubMed ID: 26627075
[No Abstract] [Full Text] [Related]
7. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies.
Santos-Juanes J; Coto-Segura P; Mas-Vidal A; Galache Osuna C
Br J Dermatol; 2010 May; 162(5):1144-6. PubMed ID: 20222926
[No Abstract] [Full Text] [Related]
8. Ustekinumab: when everything else fails?
Vitiello M; Grant A; Kerdel FA
Int J Dermatol; 2011 Apr; 50(4):478-82. PubMed ID: 21413963
[No Abstract] [Full Text] [Related]
9. Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab.
Böhner A; Roenneberg S; Eyerich K; Eberlein B; Biedermann T
JAMA Dermatol; 2016 Apr; 152(4):482-4. PubMed ID: 26650014
[No Abstract] [Full Text] [Related]
10. Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies.
Rallis E; Verros CD
Dermatol Online J; 2011 Apr; 17(4):14. PubMed ID: 21549089
[No Abstract] [Full Text] [Related]
11. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies.
Castiñeiras I; Fernández-Diaz L; Juárez Y; Lueiro M
J Dermatol; 2012 Aug; 39(8):730-1. PubMed ID: 22364316
[No Abstract] [Full Text] [Related]
12. Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab.
Downs AM
Br J Dermatol; 2010 Aug; 163(2):433-4. PubMed ID: 20456344
[No Abstract] [Full Text] [Related]
13. Efficacy of ustekinumab in palmoplantar psoriasis.
Bulai Livideanu C; Lahfa M; Mazereeuw-Hautier J; Paul C
Dermatology; 2010; 221(4):321-3. PubMed ID: 20980724
[No Abstract] [Full Text] [Related]
14. Brodalumab (Siliq
Gupta AK; Versteeg SV; Abramovits W; Vincent KD
Skinmed; 2017; 15(4):281-285. PubMed ID: 28859739
[No Abstract] [Full Text] [Related]
15. Tattoo sites and psoriasis.
Smith SF; Feldman SR
J Drugs Dermatol; 2011 Oct; 10(10):1199-200. PubMed ID: 21968672
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study.
Rigopoulos D; Gregoriou S; Makris M; Ioannides D
Dermatology; 2011; 223(4):325-9. PubMed ID: 22134046
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab reduces plasma oxidative stress in psoriasis: A case-based experience.
Becatti M; Urban ML; Taurisano G; Mannucci A; Barygina V; Pescitelli L; Prignano F; Silvestri E; Taddei N; Lotti T; Fiorillo C; Emmi G
Dermatol Ther; 2018 Sep; 31(5):e12675. PubMed ID: 30133998
[No Abstract] [Full Text] [Related]
18. Neutrophil-to-lymphocyte ratio decreases after treatment of psoriasis with therapeutic antibodies.
Zhang L; Wiles C; Martinez LR; Han G
J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):e491-e492. PubMed ID: 28502119
[No Abstract] [Full Text] [Related]
19. [Patient education. Information letter on treatment of psoriasis with infliximab (Remicade)].
Groupe de recherche sur psoriasis de Société française de dermatologie, mai 2011
Ann Dermatol Venereol; 2011 Dec; 138(12):865-7. PubMed ID: 22137633
[No Abstract] [Full Text] [Related]
20. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
Tsai TF; Song M; Shen YK; Schenkel B; Choe YB; Kim NI; Lee JH; Lee JH; Song HJ; Youn JI;
J Drugs Dermatol; 2012 Aug; 11(8):943-9. PubMed ID: 22859239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]